PDX Development and Trial Centers (PDTCs)(U54)

Funding Agency:
National Institutes of Health

This funding opportunity announcement (FOA) solicits applications for PDX (patient-derived xenografts) Development and Trial Centers (PDTCs) to serve as the laboratory research units of the PDX Development and Trial Centers Research Network (PDXNet). The PDXNet is a National Cancer Institute (NCI) program established to coordinate collaborative, large-scale development and pre-clinical testing of targeted therapeutic agents in patient-derived models to advance the vision of cancer precision medicine.

The main goals for PDTCs include:

Development of new PDX models and methods for preclinical testing of single agents and drug combinations; and

Conducting studies of response of PDX models to novel therapeutic strategies using the newly established models as well as other existing well-characterized PDX models.

It is expected that the outcomes of PDXNet research will be particularly important for the prioritization of combinations of agents in the portfolio of NCI Investigational New Drugs (NCI-IND agents), which are evaluated clinically in the NCI’s Experimental Therapeutic Clinical Trials Network (ETCTN).

PDXNet will encompass four PDTCs (to be supported by this FOA) and a single PDX Data Commons and Coordinating Center (PDCCC) (to be supported by a companion FOA, RFA-CA-17-004). In addition, collaboration between PDXNet and the NCI Patient-Derived Models Repository (PDMR) at the Frederick National Laboratory for Cancer Research (FNLCR) will be required as part of this FOA. PDTCs will be expected to collaborate with PDMR in several areas related to the goals of the program, including the development of optimized standardized procedures, and in sharing of PDX models.


  • Letter of Intent Due Date(s): 30 days prior to the application due date
  • Application Due Date(s): March 3, 2017

RFA-CA-17-003 Expiration Date March 4, 2017

Agency Website



Amount Description

Application budgets must not exceed $800,000 per year in direct costs.

Project period of 5 years is required.

Funding Type





Medical - Clinical Science
Medical - Translational

External Deadline

March 3, 2017